NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A critical roadblock in the development of an HIV-1 vaccine is our current inability to deliver HIV-1 antigens efficiently to the immune system and to prime predictable, high frequency immune responses in humans. It is also important to develop vaccine vectors that are not subject to pre-existing anti-vector immunity. For example, the high frequency of pre-existing immunity to the Ad5 vector has been shown to suppress the immunogenicity and possibly impair the safety of rAd5 vaccines for HIV-1. To overcome this hurdle, we have developed novel replication-incompetent rAd vector-based vaccines derived from rare Ad serotypes and chimeric viruses, and we are assessing the immunogenicity and protective efficacy of these novel vaccine vectors in rhesus monkeys.